Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 288.85 Million SEK | 91.91% |
| 2022 | 150.52 Million SEK | 6.19% |
| 2021 | 141.74 Million SEK | 32.91% |
| 2020 | 106.64 Million SEK | 117.45% |
| 2019 | 49.04 Million SEK | 29.65% |
| 2018 | 37.82 Million SEK | 43.8% |
| 2017 | 26.3 Million SEK | 20.38% |
| 2016 | 21.85 Million SEK | 29.19% |
| 2015 | 16.91 Million SEK | -13.54% |
| 2014 | 19.56 Million SEK | -52.8% |
| 2013 | 41.44 Million SEK | 128.26% |
| 2012 | 18.15 Million SEK | -15.31% |
| 2011 | 21.44 Million SEK | 20.34% |
| 2010 | 17.81 Million SEK | 20.72% |
| 2009 | 14.75 Million SEK | -1.73% |
| 2008 | 15.01 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 303.42 Million SEK | 0.04% |
| 2024 Q1 | 303.3 Million SEK | 5.0% |
| 2023 Q2 | 211.08 Million SEK | 7.49% |
| 2023 Q1 | 196.36 Million SEK | 30.46% |
| 2023 Q3 | 292.71 Million SEK | 38.67% |
| 2023 FY | 288.85 Million SEK | 91.91% |
| 2023 Q4 | 288.85 Million SEK | -1.32% |
| 2022 Q3 | 157.31 Million SEK | 5.35% |
| 2022 FY | 150.52 Million SEK | 6.19% |
| 2022 Q1 | 147.06 Million SEK | 3.75% |
| 2022 Q2 | 149.32 Million SEK | 1.54% |
| 2022 Q4 | 150.52 Million SEK | -4.32% |
| 2021 Q3 | 106.36 Million SEK | -0.28% |
| 2021 Q4 | 141.74 Million SEK | 33.27% |
| 2021 Q2 | 106.66 Million SEK | -1.17% |
| 2021 FY | 141.74 Million SEK | 32.91% |
| 2021 Q1 | 107.93 Million SEK | 1.2% |
| 2020 Q2 | 98.84 Million SEK | 3.68% |
| 2020 FY | 106.64 Million SEK | 117.45% |
| 2020 Q3 | 98.12 Million SEK | -0.73% |
| 2020 Q4 | 106.64 Million SEK | 8.69% |
| 2020 Q1 | 95.33 Million SEK | 94.38% |
| 2019 Q3 | 54.61 Million SEK | 27.62% |
| 2019 Q4 | 49.04 Million SEK | -10.19% |
| 2019 Q2 | 42.79 Million SEK | 8.1% |
| 2019 FY | 49.04 Million SEK | 29.65% |
| 2019 Q1 | 39.58 Million SEK | 4.65% |
| 2018 Q4 | 37.82 Million SEK | -3.51% |
| 2018 Q2 | 42.71 Million SEK | 39.73% |
| 2018 Q1 | 30.57 Million SEK | 16.22% |
| 2018 FY | 37.82 Million SEK | 43.8% |
| 2018 Q3 | 39.2 Million SEK | -8.23% |
| 2017 FY | 26.3 Million SEK | 20.38% |
| 2017 Q4 | 26.3 Million SEK | 5.34% |
| 2017 Q2 | 26.34 Million SEK | 37.25% |
| 2017 Q1 | 19.19 Million SEK | -12.15% |
| 2017 Q3 | 24.97 Million SEK | -5.22% |
| 2016 Q4 | 21.85 Million SEK | -5.64% |
| 2016 FY | 21.85 Million SEK | 29.19% |
| 2016 Q2 | 26.31 Million SEK | 21.49% |
| 2016 Q3 | 23.15 Million SEK | -12.0% |
| 2016 Q1 | 21.66 Million SEK | 28.06% |
| 2015 Q3 | 17.82 Million SEK | -29.22% |
| 2015 Q1 | 16.5 Million SEK | -15.61% |
| 2015 Q2 | 25.18 Million SEK | 52.52% |
| 2015 FY | 16.91 Million SEK | -13.54% |
| 2015 Q4 | 16.91 Million SEK | -5.09% |
| 2014 Q1 | 37.88 Million SEK | -8.59% |
| 2014 Q3 | 27.79 Million SEK | -17.29% |
| 2014 Q4 | 19.56 Million SEK | -29.61% |
| 2014 FY | 19.56 Million SEK | -52.8% |
| 2014 Q2 | 33.6 Million SEK | -11.31% |
| 2013 Q4 | 41.44 Million SEK | 106.18% |
| 2013 Q2 | 23.85 Million SEK | 79.19% |
| 2013 Q1 | 13.31 Million SEK | -26.69% |
| 2013 FY | 41.44 Million SEK | 128.26% |
| 2013 Q3 | 20.1 Million SEK | -15.72% |
| 2012 FY | 18.15 Million SEK | -15.31% |
| 2012 Q2 | 29.65 Million SEK | 63.23% |
| 2012 Q3 | 25.8 Million SEK | -12.98% |
| 2012 Q4 | 18.15 Million SEK | -29.62% |
| 2012 Q1 | 18.16 Million SEK | -15.28% |
| 2011 Q1 | 14.5 Million SEK | -18.62% |
| 2011 Q4 | 21.44 Million SEK | -13.87% |
| 2011 FY | 21.44 Million SEK | 20.34% |
| 2011 Q3 | 24.89 Million SEK | -12.25% |
| 2011 Q2 | 28.37 Million SEK | 95.66% |
| 2010 Q2 | 25.72 Million SEK | 76.87% |
| 2010 Q4 | 17.81 Million SEK | -14.08% |
| 2010 Q3 | 20.73 Million SEK | -19.39% |
| 2010 Q1 | 14.54 Million SEK | -1.46% |
| 2010 FY | 17.81 Million SEK | 20.72% |
| 2009 Q4 | 14.75 Million SEK | 0.0% |
| 2009 Q1 | 16.56 Million SEK | 0.0% |
| 2009 FY | 14.75 Million SEK | -1.73% |
| 2008 FY | 15.01 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -143.864% |
| Ziccum AB (publ) | 14.97 Million SEK | -1829.315% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1341.33% |
| BioArctic AB (publ) | 1.18 Billion SEK | 75.646% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -363.083% |
| Mendus AB (publ) | 755.95 Million SEK | 61.789% |
| Intervacc AB (publ) | 259.61 Million SEK | -11.265% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -588.427% |
| Active Biotech AB (publ) | 44 Million SEK | -556.493% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -3.628% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -364.759% |
| Aptahem AB (publ) | 63.02 Million SEK | -358.322% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 41.792% |
| Kancera AB (publ) | 65.64 Million SEK | -340.042% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 17.783% |
| Fluicell AB (publ) | 9.34 Million SEK | -2992.687% |
| Saniona AB (publ) | 64.14 Million SEK | -350.333% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -759.642% |
| Biovica International AB (publ) | 131.4 Million SEK | -119.817% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -445.168% |
| AcouSort AB (publ) | 34.51 Million SEK | -736.951% |
| Xintela AB (publ) | 18.39 Million SEK | -1470.302% |
| Abliva AB (publ) | 87.49 Million SEK | -230.126% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 62.002% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 77.046% |
| OncoZenge AB (publ) | 20.34 Million SEK | -1320.143% |
| Amniotics AB (publ) | 26.08 Million SEK | -1007.326% |
| 2cureX AB (publ) | 16.62 Million SEK | -1637.486% |
| CombiGene AB (publ) | 120.61 Million SEK | -139.493% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -4653.283% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 84.801% |
| Camurus AB (publ) | 1.9 Billion SEK | 84.859% |
| Corline Biomedical AB | 100.1 Million SEK | -188.554% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -63.085% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -105.45% |
| I-Tech AB | 152.44 Million SEK | -89.485% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 71.626% |
| Cyxone AB (publ) | 43.65 Million SEK | -561.681% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -267.073% |
| Biosergen AB | 7.2 Million SEK | -3911.346% |
| Cantargia AB (publ) | 223.71 Million SEK | -29.12% |
| NextCell Pharma AB | 81.28 Million SEK | -255.35% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 62.254% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -857.335% |
| Nanologica AB (publ) | 77.42 Million SEK | -273.06% |
| SynAct Pharma AB | 228.01 Million SEK | -26.681% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -979.315% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -1230.962% |
| LIDDS AB (publ) | 17.65 Million SEK | -1536.12% |
| Lipum AB (publ) | 12.11 Million SEK | -2285.277% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 79.37% |
| Alzinova AB (publ) | 123.18 Million SEK | -134.483% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -21.176% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -3316.404% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -238.927% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1842.679% |
| Simris Alg AB (publ) | 174.55 Million SEK | -65.485% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -33.091% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 55.799% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -231.745% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -913.249% |